Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 238

Similar articles for PubMed (Select 23079062)

1.

Treatment of advanced myelodysplastic syndrome with demethylating agents: azacitidine.

Adès L, Itzykson R, Fenaux P.

Semin Hematol. 2012 Oct;49(4):323-9. doi: 10.1053/j.seminhematol.2012.09.002. Review.

PMID:
23079062
2.

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.

Edlin R, Connock M, Tubeuf S, Round J, Fry-Smith A, Hyde C, Greenheld W.

Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10. Review.

3.

Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.

Keating GM.

Drugs. 2012 May 28;72(8):1111-36. doi: 10.2165/11209430-000000000-00000. Review. Erratum in: Drugs. 2012 Jul 30;72(11):1578.

PMID:
22571445
4.

Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

van der Helm LH, Alhan C, Wijermans PW, van Marwijk Kooy M, Schaafsma R, Biemond BJ, Beeker A, Hoogendoorn M, van Rees BP, de Weerdt O, Wegman J, Libourel WJ, Luykx-de Bakker SA, Minnema MC, Brouwer RE, Croon-de Boer F, Eefting M, Jie KS, van de Loosdrecht AA, Koedam J, Veeger NJ, Vellenga E, Huls G.

Br J Haematol. 2011 Dec;155(5):599-606. doi: 10.1111/j.1365-2141.2011.08893.x. Epub 2011 Oct 8.

PMID:
21981697
5.

Review of azacitidine trials in Intermediate-2-and High-risk myelodysplastic syndromes.

Fenaux P, Ades L.

Leuk Res. 2009 Dec;33 Suppl 2:S7-11. doi: 10.1016/S0145-2126(09)70227-9. Review.

PMID:
20004796
6.

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF.

J Clin Oncol. 2002 May 15;20(10):2429-40.

PMID:
12011120
7.

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y, Sorin L, Dreyfus F, Cluzeau T, Delaunay J, Sanhes L, Eclache V, Dartigeas C, Turlure P, Harel S, Salanoubat C, Kiladjian JJ, Fenaux P, Adès L; Groupe Francophone des Myelodysplasies (GFM).

Blood. 2010 Nov 11;116(19):3735-42. doi: 10.1182/blood-2010-03-274811. Epub 2010 Jul 27.

8.

Azacitidine has limited activity in 'real life' patients with MDS and AML: a single centre experience.

Ozbalak M, Cetiner M, Bekoz H, Atesoglu EB, Ar C, Salihoglu A, Tuzuner N, Ferhanoglu B.

Hematol Oncol. 2012 Jun;30(2):76-81. doi: 10.1002/hon.986. Epub 2011 Mar 8.

PMID:
21387357
9.

Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.

Keating GM.

Drugs. 2009;69(17):2501-18. doi: 10.2165/11202840-000000000-00000. Review.

PMID:
19911860
10.

Azacitidine for the treatment of myelodysplastic syndrome.

Cataldo VD, Cortes J, Quintás-Cardama A.

Expert Rev Anticancer Ther. 2009 Jul;9(7):875-84. doi: 10.1586/era.09.61. Review.

PMID:
19589026
11.

Safety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndrome.

Ritchie EK.

Clin Interv Aging. 2012;7:165-73. doi: 10.2147/CIA.S24659. Epub 2012 Jun 19. Review.

12.

Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

Bally C, Adès L, Renneville A, Sebert M, Eclache V, Preudhomme C, Mozziconacci MJ, de The H, Lehmann-Che J, Fenaux P.

Leuk Res. 2014 Jul;38(7):751-5. doi: 10.1016/j.leukres.2014.03.012. Epub 2014 Mar 23.

PMID:
24836762
13.

Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update.

Joeckel TE, Lübbert M.

Semin Hematol. 2012 Oct;49(4):330-41. doi: 10.1053/j.seminhematol.2012.08.001. Review.

PMID:
23079063
14.

Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).

Bally C, Thépot S, Quesnel B, Vey N, Dreyfus F, Fadlallah J, Turlure P, de Botton S, Dartigeas C, de Renzis B, Itzykson R, Fenaux P, Adès L.

Leuk Res. 2013 Jun;37(6):637-40. doi: 10.1016/j.leukres.2013.02.014. Epub 2013 Mar 15.

PMID:
23499498
15.

Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.

Harel S, Cherait A, Berthon C, Willekens C, Park S, Rigal M, Brechignac S, Thépot S, Quesnel B, Gardin C, Adès L, Fenaux P, Braun T.

Leuk Res. 2015 May;39(5):501-4. doi: 10.1016/j.leukres.2015.02.004. Epub 2015 Feb 16.

PMID:
25735917
16.

Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes.

Seymour JF, Fenaux P, Silverman LR, Mufti GJ, Hellström-Lindberg E, Santini V, List AF, Gore SD, Backstrom J, McKenzie D, Beach CL.

Crit Rev Oncol Hematol. 2010 Dec;76(3):218-27. doi: 10.1016/j.critrevonc.2010.04.005. Epub 2010 May 6.

17.

Outcome of therapy-related myeloid neoplasms treated with azacitidine.

Fianchi L, Criscuolo M, Lunghi M, Gaidano G, Breccia M, Levis A, Finelli C, Santini V, Musto P, Oliva EN, Leoni P, Aloe Spiriti A, D'Alò F, Hohaus S, Pagano L, Leone G, Voso MT.

J Hematol Oncol. 2012 Aug 1;5:44. doi: 10.1186/1756-8722-5-44.

18.

Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.

Damaj G, Duhamel A, Robin M, Beguin Y, Michallet M, Mohty M, Vigouroux S, Bories P, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Legrand F, Deconinck E, Fegueux N, Clement L, Dauriac C, Maillard N, Cornillon J, Ades L, Guillerm G, Schmidt-Tanguy A, Marjanovic Z, Park S, Rubio MT, Marolleau JP, Garnier F, Fenaux I, Yakoub-Agha I.

J Clin Oncol. 2012 Dec 20;30(36):4533-40. doi: 10.1200/JCO.2012.44.3499. Epub 2012 Oct 29.

19.

Methylation inhibitor therapy in the treatment of myelodysplastic syndrome.

Silverman LR, Mufti GJ.

Nat Clin Pract Oncol. 2005 Dec;2 Suppl 1:S12-23. Review.

PMID:
16341236
20.

Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Itzykson R, Thépot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, Vey N, Recher C, Dartigeas C, Legros L, Delaunay J, Salanoubat C, Visanica S, Stamatoullas A, Isnard F, Marfaing-Koka A, de Botton S, Chelghoum Y, Taksin AL, Plantier I, Ame S, Boehrer S, Gardin C, Beach CL, Adès L, Fenaux P; Groupe Francophone des Myelodysplasies(GFM).

Blood. 2011 Jan 13;117(2):403-11. doi: 10.1182/blood-2010-06-289280. Epub 2010 Oct 12.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk